Kellie L McIlwain

Title: Innovations by Kellie L McIlwain

Introduction

Kellie L McIlwain is a prominent inventor based in Washington, DC. She has made significant contributions to the field of biotechnology, particularly in the area of G protein-coupled receptors (GPCRs). With a total of 2 patents, her work focuses on innovative methods for diagnosing and treating various diseases and disorders.

Latest Patents

Kellie L McIlwain's latest patents include "G protein coupled receptor 85 and SREB3 knockout mice and uses thereof." This invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, along with methods for their production. The polypeptides and polynucleotides are useful in diagnosing and treating diseases and disorders. Additionally, the invention offers methods for identifying compounds, such as agonists or antagonists, using the GPCR polypeptides and polynucleotides. It also provides diagnostic assays for detecting diseases associated with inappropriate GPCR activity or levels. Another significant patent is the "Method of identifying a compound for the treatment or prevention of obesity," which shares similar applications and methodologies.

Career Highlights

Kellie L McIlwain is currently associated with Omeros Corporation, where she continues to advance her research and innovations. Her work has been instrumental in developing new therapeutic approaches that leverage the functionality of GPCRs.

Collaborations

Some of her notable coworkers include George A Gaitanaris and John E Bergmann, who have collaborated with her on various projects within the field.

Conclusion

Kellie L McIlwain's contributions to biotechnology through her patents and research are paving the way for new diagnostic and therapeutic methods. Her work exemplifies the impact of innovative thinking in addressing complex medical challenges.